Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 5/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 3/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL270122 | 0.85 | AXL (0.46) | AXLAURKAPDGFRBPDGFRAEGFR | |
| Hydrochloric Acid SCHEMBL266775 | 0.84 | AXL (0.46) | AXLAURKAPDGFRBPDGFRAEGFR | |
| SCHEMBL270434 | 0.83 | AXL (0.44) | AXLAURKAPDGFRBPDGFRAEGFR | |
| SCHEMBL270462 | 0.81 | PDGFRB (0.49) | AXLAURKAPDGFRBPDGFRAEGFR | |
| Hydrochloric Acid SCHEMBL264901 | 0.81 | PDGFRB (0.48) | AXLAURKAPDGFRBPDGFRAEGFR | |
| SCHEMBL270527 | 0.81 | FLT3 (0.47) | AXLJAK2JAK1JAK3CDK4 | |
| SCHEMBL270515 | 0.80 | SYK (0.51) | AXLAURKAPDGFRBPDGFRAJAK2 | |
| SCHEMBL264268 | 0.80 | SCN9A (0.51) | AXLAURKAEGFRJAK2JAK1 | |
| Hydrochloric Acid SCHEMBL263896 | 0.79 | SYK (0.50) | AXLAURKAPDGFRBPDGFRAJAK2 | |
| SCHEMBL264636 | 0.79 | SYK (0.65) | AXLAURKAPDGFRBPDGFRAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | AXL 376/4885AURKA 745/4885PDGFRB 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.